Share Facebook Twitter LinkedIn Pinterest Email Vertex secures NHS England reimbursement deal for Alyftrek cystic fibrosis treatment
Gentherm raises 2026 outlook while targeting $3.5B+ revenue by 2030 through Modine combination (NASDAQ:THRM)July 23, 2026